| Literature DB >> 31572276 |
Carolien A van Houdt1,2, Cornelieke S H Aarnoudse-Moens1,2,3,4, Aleid G van Wassenaer-Leemhuis1, A R Céleste Laarman5, Corine Koopman-Esseboom6, Anton H van Kaam1,5, Jaap Oosterlaan3,7.
Abstract
OBJECTIVE: Very preterm children have poorer attentional, behavioral and emotional functioning than term-born children. Problems on these domains have been linked to poorer executive function (EF). This study examined effects of a game-formatted, comprehensive EF training on attentional, behavioral and emotional functioning and self-perceived competence in very preterm children. STUDYEntities:
Keywords: EF training; computerized; executive functions; intervention; premature
Year: 2019 PMID: 31572276 PMCID: PMC6753219 DOI: 10.3389/fpsyg.2019.02100
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
FIGURE 1CONSORT Flow diagram. CBCL, Child Behavior CheckList; IQ, Intelligence Quotient. EF, Executive Function.
Demographic and neonatal medical characteristics for the three treatment groups.
| GA (M, SD) | 28.2 (1.3) | 28.0 (1.0) | 27.8 (1.4) | |
| BW (M, SD) | 1026 (256) | 1039 (179) | 1049 (267) | |
| Age (M, SD) | 10.2 (1.2) | 10.2 (1.3) | 10.3 (1.1) | |
| IQ (M, SD) | 99.0 (13.6) | 96.4 (11.7) | 100.8 (11.1) | |
| CBCL attention T-score (M, SD) | 62.8 (6.9) | 64.0 (7.6) | 64.4 (7.0) | |
| Time spent gaming | 5.5 (5.9) | 8.0 (6.3) | 8.5 (7.0) | |
| Boys (n,%) | 13(44%) | 16(62%) | 20(67%) | χ |
| Parental education level (n,%) | χ | |||
| Low | 6(21%) | 4(16%) | 1(4%) | |
| Middle | 3(10%) | 5(20%) | 11(39%) | |
| High | 20(69%) | 16(54%) | 16(57%) | |
| SGA (n,%) | 8(28%) | 4(17%) | 4(14%) | χ |
| Ventilator support (n,%) | 20(69%) | 17(65%) | 23(77%) | χ |
| BPD at 36 weeks PMA (n,%) | 7(24%) | 4(16%) | 6(21%) | χ |
| IVH I or II | 9(31%) | 6(23%) | 8(27%) | χ |
| IVH III or IV | 0(0%) | 2(8%) | 1(3%) | χ |
| PVL I | 1(3%) | 2(8%) | 0(0%) | χ |
| PVL II, III or IV | 0(0%) | 0(0%) | 0(0%) | |
| Open Ductus Botalli treated | 3(10%) | 12(46%) | 13(43%) | χ |
| Sepsis | 17(59%) | 16(62%) | 20(67%) | χ |
Improvement during training on the training tasks.
| Working memory version 1 | 3.15 (0.42) | 3.87 (0.65) | |
| Working memory version 2 | 3.25 (0.37) | 3.84 (0.71) | |
| Working memory version 3 | 3.07 (0.41) | 4.03 (0.82) | |
| Working memory version 4 | 2.95 (0.44) | 3.55 (0.77) | |
| Working memory version 5 | 2.98 (0.53) | 3.74 (0.96) | |
| Inhibition | 3.70 (1.30) | 11.42 (2.08) | |
| Cognitive Flexibility | 1.28 (0.51) | 8.63 (4.14) |
Baseline and follow-up data on the Attention Network Test for Children for the three treatment groups.
| EF training | 26.15 (9.29; 7.83 – 44.47) | 22.29 (10.68; 1.22 – 43.36) | 21.08 (11.23; −1.06 – 43.22) | Group: 0.18 |
| Placebo training | 52.45 (9.77; 33.18 – 71.72) | 38.54 (12.58; 13.72 – 3.36) | 22.79 (11.83; −0.54 – 46.11) | Time: 0.22 |
| Waitlist | 25.19 (9.25; 6.94 – 43.44) | 21.07 (9.10; 3.14 – 39.01) | 18.42 (9.60; −0.51 – 37.36) | Group × Time: 0.77 |
| EF training | 74.57 (8.63; 57.54 – 91.60) | 50.22 (9.86; 30.78 – 69.66) | 90.90 (10.34; 70.51 – 111.28) | Group:0.58 |
| Placebo training | 53.46 (9.03; 35.64 – 71.28) | 64.45 (11.54; 41.70 – 87.20) | 79.18 (10.87; 57.74 – 100.61) | Time: 0.001 |
| Waitlist | 55.35 (8.56; 38.47 – 72.23) | 79.45 (8.42; 62.84 – 96.07) | 90.70 (8.87; 73.21 – 108.18) | Group × Time: 0.053 |
| EF training | 85.90 (9.60; 66.95 – 104.83) | 57.12 (10.98; 35.47 – 78.77) | 58.04 (11.52; 35.32 – 80.76) | Group:0.25 |
| Placebo training | 97.76 (10.05; 77.93 – 117.59) | 65.69 (12.86; 40.33 – 91.06) | 61.26 (12.11; 37.37 – 85.15) | Time: <0.001∗ |
| Waitlist | 73.86 (9.53; 55.07 – 92.65) | 45.58 (9.37; 27.09 – 64.07) | 55.38 (9.87; 35.91 – 74.85) | Group × Time: 0.91 |
Baseline and follow-up data on the Strengths and Difficulties Questionnaire according to parents and teachers for the three treatment groups.
| EF training | 2.79 (0.45; 1.90 – 3.68) | 2.35 (0.47; 1.42 – 3.28) | 2.67 (0.48; 1.72 – 3.61) | Group: 0.19 |
| Placebo training | 3.46 (0.45; 2.56 – 4.36) | 2.70 (0.49; 1.72 – 3.67) | 2.90 (0.51; 1.90 – 3.90) | Time: 0.07 |
| Waitlist | 2.23 (0.42; 1.39 – 3.06) | 1.92 (0.43; 1.07 – 2.77) | 1.86 (0.44; 0.98 – 2.73) | Group × Time:0.88 |
| EF training | 1.03 (0.36; 0.31 – 1.75) | 0.72 (0.38; −0.02 – 1.47) | 0.93 (0.38; 0.18 – 1.69) | Group: 0.13 |
| Placebo training | 1.68 (0.37; 0.95 – 2.40) | 1.80 (0.39; 1.03 – 2.58) | 1.84 (0.41; 1.03 – 2.65) | Time: 0.92 |
| Waitlist | 1.55 (0.34; 0.87 – 2.23) | 1.81 (0.35; 1.12 – 2.50) | 1.69 (0.35; 0.99 – 2.39) | Group × Time:0.68 |
| EF training | 1.51 (0.39; 0.74 – 2.28) | 1.24 (0.40; 0.44 – 2.03) | 1.05 (0.41; 0.25 – 1.86) | Group: 0.18 |
| Placebo training | 2.07 (0.39; 1.29 – 2.84) | 1.50 (0.42; 0.67 – 0.33) | 1.97 (0.44; 1.11 – 2.83) | Time: 0.13 |
| Waitlist | 2.33 (0.36; 1.61 – 3.05) | 2.24 (0.37; 1.51 – 2.98) | 1.93 (0.38; 1.19 – 2.67) | Group × Time: 0.50 |
| EF training | 8.76 (0.36; 8.04 – 9.48) | 8.41 (0.38; 7.66 – 9.16) | 8.54 (0.39; 7.77 – 9.30) | Group: 0.35 |
| Placebo training | 8.20 (0.37; 7.47 – 8.93) | 7.85 (0.40; 7.06 – 8.65) | 7.68 (0.42; 6.86 – 8.50) | Time: 0.32 |
| Waitlist | 8.14 (0.34; 7.46 – 8.81) | 8.01 (0.35; 7.32 – 8.70) | 8.19 (0.36; 7.49 – 8.90) | Group × Time: 0.83 |
| EF training | 5.26 (0.45; 4.37 – 6.15) | 4.76 (0.47; 3.83 – 5.69) | 4.67 (0.48; 3.71 – 5.62) | Group: 0.04∗ |
| Placebo training | 6.44 (0.46; 5.53 – 7.35) | 6.37 (0.50; 5.38 – 7.36) | 5.56 (0.52; 4.54 – 6.58) | Time: 0.10 |
| Waitlist | 6.24 (0.42; 5.40 – 7.07) | 6.15 (0.43; 5.29 – 7.00) | 6.01 (0.44; 5.14 – 6.89) | Group × Time: 0.73 |
| EF training | 1.90 (0.40; 1.10 – 2.70) | 1.66 (0.43; 0.80 – 2.52) | 1.73 (0.45; 0.84 – 2.62) | Group: 0.62 |
| Placebo training | 1.51 (0.43; 0.65 – 2.37) | 1.58 (0.49; 0.61 – 2.55) | 1.59 (0.61; 0.40 – 2.79) | Time: 0.83 |
| Waitlist | 1.38 (0.39; 0.60 – 2.16) | 1.23 (0.43; 0.38 – 2.08) | 1.12 (0.47; 0.20 – 2.04) | Group × Time: 0.97 |
| EF training | 0.66 (0.27; 0.13 – 1.18) | 0.41 (0.30; −0.18 – 1.01) | 0.40 (0.32; −0.23 – 1.03) | Group: 0.53 |
| Placebo training | 0.76 (0.30; 0.17 – 1.35) | 0.99 (0.35; 0.29 – 1.69) | 0.75 (0.47; −0.18 – 1.67) | Time: 0.56 |
| Waitlist | 1.01 (0.26; 0.50 – 1.52) | 0.89 (0.29; 0.31 – 1.47) | 0.59 (0.34; −0.09 – 1.26) | Group × Time:0.82 |
| EF training | 1.15 (0.39; 0.38 – 1.92) | 0.61 (0.43; −0.25 – 1.47) | 0.85 (0.47; −0.08 – 1.78) | Group: 0.03∗ |
| Placebo training | 2.05 (0.43; 1.20 – 2.91) | 1.97 (0.51; 0.97 – 2.98) | 1.54 (0.67; 0.22 – 2.85) | Time: 0.24 |
| Waitlist | 2.43 (0.38; 1.69 – 3.18) | 1.97 (0.43; 1.13 – 2.81) | 2.11 (0.49; 1.14 – 3.07) | Group × Time: 0.93 |
| EF training | 7.94 (0.48; 6.99 – 8.89) | 8.34 (0.52; 7.31 – 9.37) | 7.57 (0.55; 6.49 – 8.65) | Group: 0.42 |
| Placebo training | 7.83 (0.51; 6.81 – 8.85) | 7.13 (0.60; 5.95 – 8.31) | 7.46 (0.76; 5.97 – 8.96) | Time: 0.23 |
| Waitlist | 7.58 (0.46; 6.66 – 8.50) | 6.93 (0.51; 5.92 – 7.93) | 6.85 (0.57; 5.73 – 7.98) | Group × Time: 0.35 |
| EF training | 4.39 (0.60; 3.21 – 5.57) | 3.90 (0.65; 2.60 – 5.19) | 4.14 (0.69; 2.78 – 5.50) | Group: 0.70 |
| Placebo training | 5.51 (0.66; 4.20 – 6.82) | 5.22 (0.76; 3.72 – 6.73) | 2.64 (0.97; 0.72 – 4.56) | Time: 0.02∗ |
| Waitlist | 5.09 (0.58; 3.94 – 6.23) | 4.71 (0.64; 3.44 – 5.98) | 4.61 (0.74; 3.15 – 6.08) | Group × Time: 0.14 |
Baseline and follow-up data on self-perceived competence for the three treatment groups.
| EF training | 15.12 (0.70; 13.74 – 16.50) | 16.01 (0.74; 14.55 – 17.47) | 14.56 (0.75; 13.08 – 16.04) | Group: 0.52 |
| Placebo training | 15.37 (0.73; 13.93 – 16.81) | 17.15 (0.79; 15.59 – 18.72) | 15.72 (0.79; 14.16 – 17.29) | Time: 0.003∗ |
| Waitlist | 15.50 (0.66; 14.21 – 16.80) | 16.59 (0.66; 15.28 – 17.90) | 16.18 (0.68; 14.84 – 17.51) | Group × Time: 0.58 |
| EF training | 18.54 (0.85; 16.86 – 20.21) | 18.18 (0.89; 16.43 – 19.93) | 17.79 (0.90; 16.02 – 19.57) | Group: 0.08 |
| Placebo training | 16.68 (0.88; 14.94 – 18.41) | 17.30 (0.94; 15.45 – 19.16) | 16.29 (0.94; 14.43 – 18.15) | Time: 0.31 |
| Waitlist | 19.19 (0.79; 17.62 – 20.75) | 19.43 (0.80; 17.85 – 21.01) | 18.95 (0.81; 17.34 – 20.56) | Group × Time: 0.90 |
| EF training | 17.34 (0.71; 15.93 – 18.75) | 17.35 (0.75; 15.86 – 18.84) | 17.98 (0.76; 16.47 – 19.49) | Group: 0.38 |
| Placebo training | 17.63 (0.74; 16.16 – 19.10) | 18.04 (0.80; 16.45 – 19.63) | 18.50 (0.80; 16.92 – 20.09) | Time: 0.04∗ |
| Waitlist | 17.68 (0.67; 16.35 – 19.00) | 19.55 (0.68; 18.21 – 20.89) | 19.02 (0.69; 17.66 – 20.39) | Group × Time: 0.29 |
| EF training | 19.19 (0.82; 17.56 – 20.81) | 18.89 (0.85; 17.20 – 20.58) | 18.82 (0.86; 17.12 – 20.53) | Group: 0.07 |
| Placebo training | 19.54 (0.85; 17.86 – 21.22) | 19.32 (0.90; 17.54 – 21.10) | 19.44 (0.90; 17.66 – 21.22) | Time: 0.83 |
| Waitlist | 20.56 (0.77; 19.03 – 22.08) | 21.53 (0.77; 20.00 – 23.07) | 21.65 (0.78; 20.09 – 23.20) | Group × Time: 0.36 |
| EF training | 17.63 (0.72; 16.20 – 19.06) | 18.34 (0.77; 16.82 – 19.85) | 17.65 (0.78; 16.11 – 19.19) | Group: 0.78 |
| Placebo training | 17.26 (0.76; 15.76 – 18.75) | 18.46 (0.82; 16.83 – 20.09) | 17.42 (0.82; 15.79 – 19.05) | Time: 0.06 |
| Waitlist | 18.06 (0.68; 16.71 – 19.40) | 18.89 (0.69; 17.53 – 20.25) | 17.94 (0.70; 16.55 – 19.33) | Group × Time: 0.99 |
| EF training | 20.07 (0.65; 18.78 – 21.37) | 19.97 (0.69; 18.61 – 21.33) | 20.60 (0.70; 19.23 – 21.98) | Group: 0.12 |
| Placebo training | 19.97 (0.68; 18.62 – 21.32) | 20.55 (0.73; 19.11 – 22.00) | 20.60 (0.73; 19.16 – 22.05) | Time: 0.27 |
| Waitlist | 21.35 (0.61; 20.14 – 22.57) | 22.11 (0.62; 20.89 – 23.34) | 21.69 (0.63; 20.45 – 22.94) | Group × Time: 0.70 |